Reflections on the meningococcal group C infection immunisation campaign: views from the sharp end.

Vaccine

Children's Services, Skimped Hill Health Centre, Market Place, Bracknell, Berkshire RG12 1LH, UK.

Published: June 2003

In July 1999, the Department of Health launched a campaign to immunise all children aged from 0-17 years with a new vaccine giving protection against meningococcal group C infection. Following the campaign, a survey of Immunisation Co-ordinators in England was conducted to identify strengths and weaknesses of the campaign. This paper summarises the main findings.

Download full-text PDF

Source
http://dx.doi.org/10.1016/s0264-410x(03)00160-9DOI Listing

Publication Analysis

Top Keywords

meningococcal group
8
group infection
8
reflections meningococcal
4
infection immunisation
4
campaign
4
immunisation campaign
4
campaign views
4
views sharp
4
sharp july
4
july 1999
4

Similar Publications

The AEP 2025 Vaccination and Immunization Schedule recommended for children, adolescents and pregnant women residing in Spain features the following novelties: Due to the increase in measles cases and outbreaks in recent years, we recommend advancing the second dose of measles, mumps and rubella (MMR) vaccine to 2 years of age. As a consequence of the above, since many autonomous communities (ACs) use the quadrivalent vaccine for the second dose of MMR and varicella vaccines, we recommend, for all ACs, advancing the second dose of varicella vaccine to 2 years of age. Due to the very significant increase in cases of pertussis since late 2023 and especially in 2024, we recommend advancing the dose of Tdap given in adolescence to 10-12 years of age.

View Article and Find Full Text PDF

Objective: To estimate and compare vaccination coverage among children born in 2017-2018 in São Paulo and Campinas, according to the Vaccination Coverage Survey (ICV 2020) and the National Immunization Program Information System (SI-PNI).

Methods: ICV 2020 analyzed vaccination card records. Coverage was calculated and compared to doses recorded on the SI-PNI, divided by the target population.

View Article and Find Full Text PDF

Background: This study aims to evaluate parents' knowledge about vaccination targeted for adolescents.

Methods: The cross-sectional survey was conducted between February and April 2024 in a sample of parents of adolescents attending middle and high schools in Southern Italy.

Results: Only 10.

View Article and Find Full Text PDF

Invasive meningococcal diseases (IMD) caused by Neisseria meningitidis are generally rare. They affect mostly selected age categories and risk groups of patients (in terms of age, comorbidities, or applied therapy), and the immune system and its defects may play an important modifying role. Meningococcal infections could be the first and only clinical sign of unrecognised immunodeficiency.

View Article and Find Full Text PDF

Background: A MenABCWY vaccine containing 4CMenB and MenACWY-CRM vaccine components has been developed to protect against the five meningococcal serogroups that cause most invasive disease cases.

Methods: In this phase 3 study (NCT04707391), healthy participants aged 15-25 years, who had received MenACWY vaccination ≥4 years previously, were randomized (1:1) to receive two MenABCWY doses six months apart or one MenACWY-CRM dose. Primary objectives were to demonstrate the non-inferiority of MenABCWY 1 month post-vaccination versus MenACWY-CRM, with a lower limit of 2-sided 95% confidence interval above -10% for group differences in 4-fold rise in human serum bactericidal antibody (hSBA) titers against serogroups ACWY, and to evaluate reactogenicity and safety.

View Article and Find Full Text PDF

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!